Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm; Debra Fayter; Bram L. T. Ramaekers; Svenja Petersohn; Rob Riemsma; Nigel Armstrong; Xavier Pouwels; Willem Witlox; Caro Noake; Gillian Worthy; Jos Kleijnen; Manuela A. Joore

doi:10.1007/s40273-019-00792-7

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm^*, Debra Fayter, Bram L. T. Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy, Jos Kleijnen, Manuela A. Joore

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

Original language	English
Pages (from-to)	1195-1207
Number of pages	13
Journal	Pharmacoeconomics
Volume	37
Issue number	10
DOIs	https://doi.org/10.1007/s40273-019-00792-7
Publication status	Published - Oct 2019

Keywords

BRENTUXIMAB VEDOTIN
HEALTH
DESIGN

Cite this

Grimm, S. E., Fayter, D., Ramaekers, B. L. T., Petersohn, S., Riemsma, R., Armstrong, N., Pouwels, X., Witlox, W., Noake, C., Worthy, G., Kleijnen, J., & Joore, M. A. (2019). Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 37(10), 1195-1207. https://doi.org/10.1007/s40273-019-00792-7

Grimm, Sabine E. ; Fayter, Debra ; Ramaekers, Bram L. T. ; Petersohn, Svenja ; Riemsma, Rob ; Armstrong, Nigel ; Pouwels, Xavier ; Witlox, Willem ; Noake, Caro ; Worthy, Gillian ; Kleijnen, Jos ; Joore, Manuela A. / Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. In: Pharmacoeconomics. 2019 ; Vol. 37, No. 10. pp. 1195-1207.

@article{882bd767ae3d401e930e7a72905212d8,

title = "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

keywords = "BRENTUXIMAB VEDOTIN, HEALTH, DESIGN",

author = "Grimm, {Sabine E.} and Debra Fayter and Ramaekers, {Bram L. T.} and Svenja Petersohn and Rob Riemsma and Nigel Armstrong and Xavier Pouwels and Willem Witlox and Caro Noake and Gillian Worthy and Jos Kleijnen and Joore, {Manuela A.}",

year = "2019",

month = oct

doi = "10.1007/s40273-019-00792-7",

language = "English",

volume = "37",

pages = "1195--1207",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "10",

}

Grimm, SE, Fayter, D, Ramaekers, BLT , Petersohn, S, Riemsma, R, Armstrong, N, Pouwels, X , Witlox, W, Noake, C, Worthy, G, Kleijnen, J & Joore, MA 2019, 'Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 37, no. 10, pp. 1195-1207. https://doi.org/10.1007/s40273-019-00792-7

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Grimm, Sabine E.; Fayter, Debra; Ramaekers, Bram L. T.; Petersohn, Svenja; Riemsma, Rob; Armstrong, Nigel; Pouwels, Xavier ; Witlox, Willem; Noake, Caro; Worthy, Gillian; Kleijnen, Jos ; Joore, Manuela A.

In: Pharmacoeconomics, Vol. 37, No. 10, 10.2019, p. 1195-1207.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma

T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Grimm, Sabine E.

AU - Fayter, Debra

AU - Ramaekers, Bram L. T.

AU - Petersohn, Svenja

AU - Riemsma, Rob

AU - Armstrong, Nigel

AU - Pouwels, Xavier

AU - Witlox, Willem

AU - Noake, Caro

AU - Worthy, Gillian

AU - Kleijnen, Jos

AU - Joore, Manuela A.

PY - 2019/10

Y1 - 2019/10

KW - BRENTUXIMAB VEDOTIN

KW - HEALTH

KW - DESIGN

U2 - 10.1007/s40273-019-00792-7

DO - 10.1007/s40273-019-00792-7

M3 - Review article

VL - 37

SP - 1195

EP - 1207

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 10

ER -

Access to Document

10.1007/s40273-019-00792-7